Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 7/20 | 0.46 |
| ▸ | PDE9A | O76083 | 13/20 | 0.46 |
| ▸ | PDE1A | P54750 | 6/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21300097 | 0.94 | PDE9A (0.42) | PDE1BPDE9APDE1APDE1CGRIA1 | |
| SCHEMBL471001 | 0.82 | PDE9A (0.54) | PDE1BPDE9APDE1APDE1CPDE5A | |
| SCHEMBL14827029 | 0.82 | PDE9A (0.54) | PDE1BPDE9APDE1APDE1CPDE5A | |
| SCHEMBL7908668 | 0.80 | PDE9A (0.54) | PDE1BPDE9APDE1APDE1CPDE5A | |
| SCHEMBL18214680 | 0.79 | PDE9A (0.51) | PDE1BPDE9APDE5A | |
| SCHEMBL12045037 | 0.79 | PDE9A (0.51) | PDE1BPDE9APDE1APDE1CPDE5A | |
| SCHEMBL21300059 | 0.79 | PDE9A (0.42) | PDE1BPDE9APDE1APDE1CPDE5A | |
| SCHEMBL12045040 | 0.78 | PDE9A (0.48) | PDE1BPDE9APDE1APDE1CPDE5A | |
| SCHEMBL470993 | 0.77 | PDE9A (0.50) | PDE1BPDE9APDE1APDE1CPDE5A | |
| SCHEMBL12045041 | 0.77 | PDE9A (0.48) | PDE1BPDE9APDE1APDE1CPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010101230-A1 | QUINOXALINE COMPOUNDS | アステラス製薬株式会社 (JP) | 2010-09-10 | — | — | WO | disclosed |